(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

Verve Therapeutics stock jumped after a report said pharmaceutical giant Eli Lilly is in advanced talks to buy the ...

In April, Verve tweaked the development of the first PCSK9 inhibitor in its programme (VERVE-101) after a trial revealed ...

Eli Lilly is in talks to buy gene editing partner Verve Therapeutics for up to $1.3 billion, according to a report in ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

SunRun shares are plunging 25%, SolarEdge Technologies stock is diving 20%, and Enphase Energy is sliding 15% after Senate Republicans proposed [an end to win ...

Yields on the benchmark 10-year fell about 3 basis points to 4.42%. Among other movers, Eli Lilly is in advanced talks to ...

Verve Therapeutics is at the forefront of a new ... Partnership with Eli Lilly: Verve’s collaboration with Eli Lilly (NYSE:LLY) is a significant asset for the company. Analysts anticipate ...

Verve Therapeutics continues to engage with investors, offering insights into their clinical trials and future plans. The company is poised for several key milestones, including potential ...

Oil demand will peak at 105.6 million barrels per day (bpd) by 2029 and then fall slightly in 2030, a table in the Paris-based IEA’s annual report shows. At the same time, global production capacity ...